CD8A and neoplasm: In HNSCC, monotherapy targeting TIM-3 has demonstrated modest efficacy in the gfbr1/Pten 2cKO mouse model, significantly reducing tumour volume and increasing CD4+ and CD8+ T cell populations within the TME and periphery, while also decreasing MDSC counts [84].